ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Rigel Pharmaceuticals will shed 20% of its workforce, or 36 employees, as it focuses on compounds in preclinical and clinical studies and halts research programs in virology and oncology. Rigel will also wait to secure a partner for its lead candidate, R788, in hopes that results from Phase II clinical trials will raise the drug's value. King Pharmaceuticals is shedding 760 positions, or about 22% of its workforce, as it integrates Alpharma, the specialty drug company it bought last year for $1.6 billion. Another firm, Alexza Pharmaceuticals, is slashing one-third of its workforce, or 52 people, to devote cash to the development of AZ-003, an inhaled version of the schizophrenia drug loxapine. Meanwhile, Hollis-Eden Pharmaceuticals will cut 20 jobs, or about 33% of its staff, and is freezing salaries and suspending bonuses for remaining employees.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X